Criteria for patient access of new technologies: Impact on regulatory sciences
- At: 2012 FIP Congress in Amsterdam (the Netherlands)
- Type: Presentation
- By: LEUFKENS, Bert (Utrecht University, Utrecht Institute for Pharmaceutical Sciences, Utrecht, Netherlands)
Weighing the benefit-risk balance of medicines thorough their lifecycle is a complex challenge given the evidence that is needed to take a justified decision in an area that is full of uncertainties on clinical benefits, possible safety concerns and long-term outcomes. Over the last decades an increasing mass of science, assessment methods and.. The access to the whole abstract and the presentation file is available to FIP members and to congress participants of that specific congress.